IP Library › Granted Patent US 10,201,608
Granted Patent B2
US 10,201,608 · App. 15/955,393 · Granted Feb 12, 2019

Polynucleotides encoding humanized anti-CD40 antibodies

Inventors: Bo Yu (Newton, MA); Rijian Wang (Newton, MA); Keith Reimann (Newton, MA)
Assignee: Primatope Therapeutics Inc.
A61K39/39558A61K31/436A61K39/395A61K45/06C07K16/18C07K16/2878A61K38/00Y02A50/414Y02A50/423
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,201,608
App. No.
15/955,393
Granted
Feb 12, 2019
Kind
B2
Abstract

The present disclosure relates to anti-CD40 antibodies, such as humanized anti-CD40 antibodies, that may be used in various therapeutic, prophylactic and diagnostic methods. The antibodies generally block the ability of CD40 to bind CD154 and do so without activating the cell expressing CD40 (e.g., a B cell). The present antibodies or fragments thereof may be used to reduce complications associated with organ or tissue transplantation.

Claims (12)

1. A polynucleotide encoding a humanized anti-CD40 antibody or a CD40-binding portion thereof, the humanized anti-CD40 antibody or CD40-binding portion thereof comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 21, and wherein the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 23.

2. A vector comprising the polynucleotide of claim 1 .

3. A cell comprising the vector of claim 2 .

4. A method of producing the humanized anti-CD40 antibody or a CD40-binding portion thereof encoded by the polynucleotide of claim 1 , the method comprising the steps of:

(a) culturing the cells of claim 3 in culture medium under conditions wherein the polynucleotide is expressed, thereby producing at least one polypeptide comprising the humanized anti-CD40 antibody or a CD40-binding portion thereof; and

(b) recovering the polypeptide from the cells or culture medium.

5. The polynucleotide of claim 1 , wherein the humanized anti-CD40 antibody or a CD40-binding portion thereof is selected from the group consisting of: (a) a whole immunoglobulin molecule; (b) an scFv; (c) a Fab fragment; (d) an F(ab′)2; and (e) a disulfide linked Fv.

6. The polynucleotide of claim 1 , wherein the humanized anti-CD40 antibody or a CD40-binding portion thereof comprises at least one constant domain selected from the group consisting of: a) an IgG constant domain; and (b) an IgA constant domain.

7. The polynucleotide of claim 1 , wherein the humanized anti-CD40 antibody or a CD40-binding portion thereof comprises at least one human constant domain.

8. A composition comprising the polynucleotide of claim 1 .

9. A composition comprising the vector of claim 2 .

10. A composition comprising the cell of claim 3 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 18, 2018
From: YU, BO; WANG, RIJIAN; REIMANN, KEITH
To: PRIMATOPE THERAPEUTICS INC.
Reel/Frame 045577/0630 →
Continuity (4)
Division 15829352 · Dec 1, 2017
Continuation PCTUS2016050114 · Sep 2, 2016
Provisional Application 62214411 · Sep 4, 2015
Related Publication 20180280507A1 · Oct 4, 2018
Cited By (2)
US 12,234,294 US 12,514,924